Literature DB >> 14968112

Identification of NPM-ALK interacting proteins by tandem mass spectrometry.

David K Crockett1, Zhaosheng Lin, Kojo S J Elenitoba-Johnson, Megan S Lim.   

Abstract

Constitutive overexpression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is a key oncogenic event in anaplastic large-cell lymphomas with the characteristic chromosomal aberration t(2;5)(p23;q35). Proteins that interact with ALK tyrosine kinase play important roles in mediating downstream cellular signals, and are potential targets for novel therapies. Using a functional proteomic approach, we determined the identity of proteins that interact with the ALK tyrosine kinase by co-immunoprecipitation with anti-ALK antibody, followed by electrospray ionization and tandem mass spectrometry (MS/MS). A total of 46 proteins were identified as unique to the ALK immunocomplex using monoclonal and polyclonal antibodies, while 11 proteins were identified in the NPM immunocomplex. Previously reported proteins in the ALK signal pathway were identified including PI3-K, Jak2, Jak3, Stat3, Grb2, IRS, and PLCgamma1. More importantly, many proteins previously not recognized to be associated with NPM-ALK, but with potential NPM-ALK interacting protein domains, were identified. These include adaptor molecules (SOCS, Rho-GTPase activating protein, RAB35), kinases (MEK kinase 1 and 4, PKC, MLCK, cyclin G-associated kinase, EphA1, JNK kinase, MAP kinase 1), phosphatases (meprin, PTPK, protein phosphatase 2 subunit), and heat shock proteins (Hsp60 precursor). Proteins identified by MS were confirmed by Western blotting and reciprocal immunoprecipitation. This study demonstrates the utility of antibody immunoprecipitation and subsequent peptide identification by tandem mass spectrometry for the elucidation of ALK-binding proteins, and its potential signal transduction pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14968112     DOI: 10.1038/sj.onc.1207398

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Evaluation of enrichment techniques for mass spectrometry: identification of tyrosine phosphoproteins in cancer cells.

Authors:  Jonathan A Schumacher; David K Crockett; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

Review 2.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

3.  NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

Authors:  Annamaria Galietta; Rosalind H Gunby; Sara Redaelli; Paola Stano; Cristiana Carniti; Angela Bachi; Philip W Tucker; Carmen J Tartari; Ching-Jung Huang; Emanuela Colombo; Karen Pulford; Miriam Puttini; Rocco G Piazza; Holger Ruchatz; Antonello Villa; Arianna Donella-Deana; Oriano Marin; Danilo Perrotti; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2007-05-30       Impact factor: 22.113

4.  p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.

Authors:  Chiara Ambrogio; Claudia Voena; Andrea D Manazza; Roberto Piva; Ludovica Riera; Laura Barberis; Carlotta Costa; Guido Tarone; Paola Defilippi; Emilio Hirsch; Elisabetta Boeri Erba; Shabaz Mohammed; Ole N Jensen; Giorgio Palestro; Giorgio Inghirami; Roberto Chiarle
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

5.  IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.

Authors:  Jennifer Dien Bard; Pascal Gelebart; Mona Anand; Zoulika Zak; Samar A Hegazy; Hesham M Amin; Raymond Lai
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

6.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

7.  Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126.

Authors:  M Ito; N Zhao; Z Zeng; C C Chang; Y Zu
Journal:  Cancer Gene Ther       Date:  2010-05-07       Impact factor: 5.987

8.  NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling.

Authors:  Mikael S Lindström
Journal:  Biochem Res Int       Date:  2010-10-05

9.  JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.

Authors:  A Bouchekioua; L Scourzic; O de Wever; Y Zhang; P Cervera; A Aline-Fardin; T Mercher; P Gaulard; R Nyga; D Jeziorowska; L Douay; W Vainchenker; F Louache; C Gespach; E Solary; P Coppo
Journal:  Leukemia       Date:  2013-05-21       Impact factor: 11.528

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.